2026-03-30

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

2026-03-25

ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025

2026-03-23

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT)

2026-03-13

DATE OF BOARD MEETING

2026-03-06

VOLUNTARY ANNOUNCEMENT - (1) UNUSUAL PRICE MOVEMENTS; AND (2) APPROVAL OF IND APPLICATION OF IMM0306S (SUBCUTANEOUS FORMULATION) FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY THE NMPA

2026-03-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February, 2026

2026-03-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 February, 2026

2026-02-10

CONNECTED TRANSACTION - THE LOAN AGREEMENT

2026-02-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2026

2026-01-21

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT)

2026-01-21

VOLUNTARY ANNOUNCEMENT - UPDATES ON THE CLINICAL TRIAL OF IMM01 (TIMDARPACEPT)

2026-01-12

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS

2026-01-12

VOLUNTARY ANNOUNCEMENT - APPROVAL BY NMPA FOR CLINICAL TRIAL OF IMM01 (TIMDARPACEPT) FOR ATHEROSCLEROSIS

2026-01-07

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025

2026-01-07

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2025

2026-01-06

INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M

2026-01-06

INSIDE INFORMATION - IMMUNEONCO TO REGAIN GLOBAL RIGHTS TO IMM2510 AND IMM27M

2025-12-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025

2025-12-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2025

2025-12-03

VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD